CORD-19:c654596857bce9cdd64ffc51842048643107348c / 137345-137490 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/c654596857bce9cdd64ffc51842048643107348c","sourcedb":"CORD-19","sourceid":"c654596857bce9cdd64ffc51842048643107348c","text":"To compare the safety and efficacy of once-daily moxifloxacin with once-daily ceftriaxone in the treatment of CAP in HIV-infected patients (pts).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1143","span":{"begin":0,"end":145},"obj":"Sentence"},{"id":"T93927","span":{"begin":0,"end":145},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T1143","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T93927","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T326","span":{"begin":0,"end":145},"obj":"Sentence"}],"attributes":[{"subj":"T326","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93ecd8","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ecbd93"}]}]}}